

LABOMAR

LABOMAR MID & SMALL IN MILAN

Milan, November 30th, 2022



WALTER BERTIN



Founder & CEO

Founded Labomar in 1998 from the “Farmacia Bertin”

Member of Assindustria Veneto Centro since 2012

Graduated in pharmaceutical science and completed a Master degree in Lean Mangement

CLAUDIO DE NADAI



IR & Board Director

Consultant for Labomar since 2007 on financial strategy and Board Member since 2018, he led the asset deal of ImportFab and Welcare

After 13 yars as CFO and General Manager of an Italian SME and a past entrepreneurial experience in agri-food, he founded BModel (corporate finance boutique)

NICOLA TOMASINI



CFO

Joined Labomar Group at the end of 2022 and appointed as CFO

Professionally matured in Audit and International M&A roles at PwC, has further developed 10 years of experience as Business & Financial Controller and CFO in listed and PE backed companies.

FRANCESCO DA RIVA



Head of Sales

Significant experience in Labomar, first as Head of Foreign Sales and since the beginning of 2020 as Head of Sales and Commercial Networks

Extensive previous experience as Senior Consultant in Strategy and Business Planning

Education: MiMAC 1 (SDA Bocconi School of Management) EMBA 16 (CUOA Business School)

1

*Heritage,
Vision & Mission,
Sustainability*

2

*Labomar
Stand Alone*

3

*Labomar Business
Model Evolution*

4

*1H 2022 Results,
3Q 2022 Revenues
and 2022 Guidance*

5

*Focus Single
Controlled Companies*

1

*Heritage,
Vision & Mission,
Sustainability*

2

*Labomar
Stand Alone*

3


*Labomar Business
Model Evolution*

4

*1H 2022 Results,
3Q 2022 Revenues
and 2022 Guidance*

5

*Focus Single
Controlled Companies*



Source: Management



VISION

We improve well-being and the quality of people life

MISSION

We work together with passion, to conceive and manufacture products and services for well-being, with respect to the environment.

We innovate with courage, proud to belong to a great family



“We strongly believe
in sustainability




OUR GOAL





SHARED
BENEFIT
GOALS



1

*Heritage,
Vision & Mission,
Sustainability*

2

*Labomar
Stand Alone*

3

*Labomar Business
Model Evolution*

4

*1H 2022 Results,
3Q 2022 Revenues
and 2022 Guidance*

5

*Focus Single
Controlled Companies*



Labomar is a One Stop Shop CDMO, able to produce a wide range of nutraceutical products, medical devices, foods for special medical purposes, both taylor made and ready to sell

A wide range of pharmaceutical forms and therapeutical areas makes up our taylor made offer

FORMS	2021
Liquids	35,09%
Tablets	24,96%
Powders	21,43%
Capsules	9,30%
Others	6,47%
Microtabs	1,36%
Gel&Creams	0,81%
Softgel	0,59%
Total	100%

THERAPEUTICS AREAS	2021
Others	23,27%
Probiotics	17,22%
Gastroenterology	12,39%
Vitamins & Minerals	10,02%
Cough & Cold	7,51%
Sleep and stress Disorders	7,00%
Cardiovascular	6,16%
Energy	4,42%
Antiox	4,17%
FSMP	3,14%
Immunity	2,49%
Gynecology	2,22%
Total	100%



RISK DIVERSIFICATION

READY TO SELL PORTFOLIO

LABOMAR



LABOMAR PORTFOLIO 2021




**This is possible thanks to Labomar Innovator DNA
and its pro-active scientific marketing activities**



INNOVATOR DNA

Labomar core activities consist on scientific research and development of constantly new and patented technologies






SCIENTIFIC MARKETING


Labomar constantly invests in scientific marketing research in order to bring novelty to the market and give scientific technical support to the commercial proposition



% IP Turnover 31.12.2021




*Note: Data only referred to Labomar stand alone (2021).
In 2020, the % were 30% Turnover from IP, 70% Others*



LABOMAR R&D activities focus on developing **PATENTS AND TECHNOLOGIES**, aiming to improve the DELIVERY OF POORLY ABSORBABLE SUBSTANCES

with unique salesforce for unparalleled client coverage¹



1. Only referred to Labomar stand alone
2. "BDM" means "Business Development Manager"

1

*Heritage,
Vision & Mission,
Sustainability*

2

*Labomar
Stand Alone*

3

*Labomar Business
Model Evolution*

4


*1H 2022 Results,
3Q 2022 Revenues
and 2022 Guidance*

5

*Focus Single
Controlled Companies*

*Labomar, through the **M&A Process** carried out in the last years, is becoming a **system integrator** with a presence on the entire value chain*


AUTONOMOUS FURTHER MARKET OPPORTUNITIES



R&D

LABOMAR
NEXT

LABIOTRE



*All pharmaceutical form
and all therapeutics areas*

Categories
Probiotics
Cough & Cold
Sleep & Stress disorders
Vitamins
Cardiovascular
Gastroenterology
Antioxidants
Energy
Minerals
FSMP
Immune System
Laxatives
Skin inflammation due to radio/chemio therapy
Wound treatment
Others

LIQUIDS	Syrup, Suspension, Emulsion, Nanoemulsion, Extemporaneus Solutions
TABLETS	Chewable, Swallowable, Microtablets 3mm, Sublingual, Film covered, Modified release, Multilayer, Gastro-resistant
POWDERS	Soluble, Orodispersible, Granulated, Gastro-resistant
CAPSULES	Hard capsules, animal and vegetal origin, softgel capsules
WET WIPES AND GLOVES	Premoistened, sterile gauze and glove
OTHER	Creams, Gels, Ointments, Lotions



Go to Market



LABOVAR

Big pharma company



Example of products



1

*Heritage,
Vision & Mission,
Sustainability*

2

*Labomar
Stand Alone*

3

*Labomar Business
Model Evolution*


4

*1H 2022 Results,
3Q 2022 Revenues
and 2022 Guidance*

5


*Focus Single
Controlled Companies*

Labomar 1H 2022 Results




A very important growth in revenues, thanks to the contribution of Labomar and ImportFab in line with organic growth expectations, and the new Companies added in the perimeter.

(€/ml)




On a like-for-like basis, group revenues increased to double digits, in line with 2022 guidance. The further contribution generated by the inclusion of Welcare Group and Labiotre is significant.




After suffering the effects of the pandemic in the first half of 2021, Company profit returned to pre-pandemic levels in the second half of 2021.


In the first half of 2022, the Group confirmed the upward trend and benefited from the corporate integration of Welcare Group and Labiotre.




Despite the growth in amortization and depreciation, margin recovery is also evident at the EBIT level.



The Group realized a **growth of 45,4% in Net Profit in 2022**, minus the non-recurring costs that occurred in 2021.




Net Working Capital evolution is linked to a growth in dimension, but especially to a prudent policy of advance purchases that has made possible to better defend the profitability of the Company, without causing too much tension in customer relationships.





Net Financial Position growth in H1 2022 is linked to inventory growth, which has anticipated, at least partially, the price increases. Compared to H1 2021, the increase is related to the acquisitions of Welcare Group and Labiotre finalized in H2 2021. Finally, it is useful to highlight the actual financial bank debt, with respect to the debts for rights of use and the valuation of future call / put.

3Q 2022 Labomar revenues



Perimeter expansion effect



A very important growth in revenues generated by all Group companies.

Note: **Revenues Like4Like** include Labomar SpA, Enterprises ImportFab Inc. and Welcare Group, the latter for the relevant months, having been acquired in July 2021; not including Labiotre Srl, control of which was acquired in November 2021.

On the base of 1H 2022 Labomar Group Results and 3Q 2022 Labomar Group Revenues, we can confirm IMI and CFO estimates for the Full Year 2022, as for their last Researches.

<i>(€/ml)</i>	IMI & CFO Consensus
REVENUES	83,5
EBITDA	15,0

Difficulties in the procurement of some raw materials
(lengthening of times and increase in costs);

Some operational problems still related to Covid-19
(i.e. absence of workers due to positivity, fewer visits than usual by Medical Representatives to Prescribers and Pharmacists, ...);

Russia-Ukraine War impact

HOW LABOMAR FACES THESE SITUATIONS?

Reinforcing its procurement organization & searching continuously new back up suppliers

Managing to incentive a lower absenteeism rate & organizing a 'long bleachers' of temporary workers

Avoiding any Russian or Ukrainian addition, either in Customers or in Suppliers

1

*Heritage,
Vision & Mission,
Sustainability*

2

*Labomar
Stand Alone*

3

*Labomar Business
Model Evolution*

4

*1H 2022 Results,
3Q 2022 Revenues
and 2022 Guidance*

5

*Focus Single
Controlled Companies*



LABOMAR
NEXT

a BLUE OCEAN Project
for a more responsible
and sustainable production,
in accordance with




The Company studies solutions derived from specific plants rich in active ingredients that could support and give ideas to R&D Dept.


raw materials, ingredients




NUTRACEUTICALS



PHARMACEUTICALS



COSMETICS



SUPER FOOD

3 ONGOING R&D PROJECTS:



Next generation
nutraceutical ingredients



Medical Cannabis



Micro greens



a strategic integration
upstream of the supply chain

Labiotre aim is the manufacturing of
botanical extracts with a full control
on the value chain, in order to guarantee
the highest qualitative standards.





FOCUS ON SOFT-GELS


A brand new plant, built with the highest quality standards, that offers flexibility of the batch sizes, owing to the different production lines, thanks to the deep expertise of the technicians involved in the manufacturing process.



WELCARE
Protecting People - Caring for Nature

a boost for internationalization and complementary business

It develops safe, effective and innovative solutions to prevent and solve skin infections and lesions related to hygiene and pathologies.



10%
of yearly turnover is
invested in R&D and
production capacity

present in more than

20
markets across **5**
continents

A CLEAR CROSS SELLING SYNERGY WITH A BRANDED COMPANY

—
Product development, regulatory assistance, manufacturing for

—
More than 20 foreign markets (i.e. well based in Middle East)

—
Market channels: hospitals, hospices, house assistance, pharmacy



an Highway for North American presence

It manufactures semi-solid and liquid products and it is, essentially, a benchmark for modern, efficient production, assured through the use of highly performing equipment.

PHARMACEUTICAL
FORMULATIONS

NUTRACEUTICAL dietary
supplement manufacturing

COSMETIC and
cosmeceutical products



Labomar Synergies with ImportFab:

Labomar R&D dept offers a lot of production solution to Importfab, to be realized and distributed in Canada and North America through its current customers and prospects

Opportunities for Labomar to serve its typical customers that distribute in Canada and North America, thanks to Importfab manufacturing capabilities and its certifications.





The diagram illustrates the formation of Labovar through the combination of Labomar and Sesa. On the left, the word "LABOMAR" is displayed in white capital letters within a black rectangular box. This is followed by a light blue plus sign. To the right of the plus sign is the "Sesa" logo, which features the word "Sesa" in a stylized blue font with a lowercase "s.p.a" in a smaller font to its right. This is followed by a light blue equals sign. Finally, the word "LABOVAR" is shown in large, bold, black capital letters on the right side of the equation.


WHO

Labomar in partnership with Sesa (EuroNext Star Public Company, 2,2 bn.€ of revenues), reference player in Italy in technological innovation and digital services for the business segment, through its controlled Company **Adiacent**, specialised in digital e-commerce platforms and digital marketing for international enterprises on the Far East Market.

WHAT

New.Co. (51% Labomar) focused on the development of **Chinese Nutraceutical Market**.


First revenues from the beginning of 2023



A great opportunity to operate in one of the largest marketplaces in the world (China),

Bringing top-quality and branded products in a business model focused, firstly, on digital sales platforms (T MALL)


And opening physical distribution channels, as a next step.



Source: Financial Statement Labomar Group 2021

Thank you for your attention!

LABOMAR



Labomar S.p.a.
Via N. Sauro, 35/I - 31036 Istrana (TV)
P-Iva IT03412720264
tel: 0422 7312 - fax: 0422 836547
www.labomar.com - contact@labomar.com